Worksite Cancer Screening Boosts Employee Morale

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

FORT LAUDERDALE, Fla-Worksite cancer screening programs are designed to help reduce cancer morbidity and mortality among employees, but have the added benefit of enhancing the employer's corporate image and boosting employee morale.

FORT LAUDERDALE, Fla-Worksite cancer screening programs are designedto help reduce cancer morbidity and mortality among employees,but have the added benefit of enhancing the employer's corporateimage and boosting employee morale.

"Cancer screening and education programs enhance a company'sreputation as a leader in employee health initiatives," saidRobert C. Black, president of Zeneca Pharmaceuticals, at the secondannual conference of the Industries' Coalition Against Cancer(ICAC).

Mr. Black noted that the worksite screening program at Zenecahas been applauded both within the company and within the communitywhere it operates, and receives frequent media attention, especiallythe breast cancer program, which has found eight cases of breastcancer in just 5 years.

Zeneca is viewed as a leader in helping large and small companiesand organizations develop and implement breast cancer screeningprograms, he said, due to its sponsorship of two Public BroadcastingSystem video conferences on worksite screening, as well as ICAC.

He said that the screening programs have helped improve employeemorale company wide. "Those who participate in our cancerscreening program have become its most effective promoters,"he said. "They truly become ambassadors for the company,both within its walls and within the local community."

Furthermore, when cancers are found, he said, Zeneca employeesrally around their coworkers with cancer by working extra hoursto give them time off, giving up vacation time to take over assignments,and providing a support system with hospital and home visits.In short, he said, "our employees do all the things thatmembers of a family, in this case a corporate family, do for eachother."

Recent Videos
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content